Pub Date : 2023-03-13DOI: 10.25251/skin.7.supp.171
Sarah Matthews, Gary Peck, R. Reifer, M. Hyde, Burkhard Jansen, M. Skelsey
{"title":"Visual Assessment and Dermoscopy Enhanced by Non-invasive Genomic Testing","authors":"Sarah Matthews, Gary Peck, R. Reifer, M. Hyde, Burkhard Jansen, M. Skelsey","doi":"10.25251/skin.7.supp.171","DOIUrl":"https://doi.org/10.25251/skin.7.supp.171","url":null,"abstract":"","PeriodicalId":74803,"journal":{"name":"Skin (Milwood, N.Y.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45778489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-03-13DOI: 10.25251/skin.7.supp.157
H. Baldwin, J. D. Del Rosso, L. Kircik, L. Stein Gold, Adelaide Hebert, E. Rieder, A. Alexis, J. Harper, R. Fried, Siva Narayanan, V. Koscielny, I. Kasujee, E. Graber
Introduction: The objective of this analysis was to evaluate facial IGA and the associated IGA success, stratified by the use of concomitant acne medications, among AV patients administered sarecycline in community practices across the U.S. Methods: A single-arm, prospective cohort study (PROSES) was conducted with moderate-to-severe non-nodular AV patients >9 years who were prescribed sarecycline in real-world community practices in the US. Facial IGA of AV status was collected on a five-point adjectival response scale (0(clear)-4(severe)). IGA success at week-12 was defined as >2-grade improvement and score 0-clear or 1-almost clear at week-12. Proportion of patients achieving IGA success was analyzed, stratified by the use of any concomitant AV medication during the study (Yes vs. No (monotherapy)). Results: A total of 253 AV patients completed the study (adults 60.08% (mean age 26.63); pediatric 39.92% (mean age 14.81); female: 66.40%; white/caucasian: 68.38%, african-american: 8.70%; other races: 22.92%). Per IGA at baseline, 86.56% & 13.44% had moderate and severe AV, respectively. Key concomitant treatments for AV observed during the study included: topical retinoids (24.51%), topical antibiotics (13.44%), benzoyl peroxide (5.93%), topical dapsone (5.14%) and other (17.00%; predominantly adapalene/benzoyl peroxide). Half of the patients (49.80%) were on sarecycline monotherapy (i.e., did not use any concomitant treatments for AV). For the overall study cohort, IGA success at week-12 was 58.89%. At week-12, IGA success was 59.84% among patients using concomitant AV medications, and 57.94% among patients using no concomitant AV medications (i.e., on sarecycline monotherapy). Conclusion: Within the study cohort administered sarecycline, a narrow-spectrum, tetracycline-derived antibiotic, for 12 weeks, majority of patients achieved IGA success at week-12, and the outcomes were similar among patients on sarecycline monotherapy and those on concomitant AV medications.
{"title":"Investigator global assessment (IGA) of Acne Vulgaris and IGA Success among patients with moderate to severe non-nodular Acne Vulgaris (AV) administered sarecycline in community practices across the U.S in PROSES study: Analysis by concomitant medication","authors":"H. Baldwin, J. D. Del Rosso, L. Kircik, L. Stein Gold, Adelaide Hebert, E. Rieder, A. Alexis, J. Harper, R. Fried, Siva Narayanan, V. Koscielny, I. Kasujee, E. Graber","doi":"10.25251/skin.7.supp.157","DOIUrl":"https://doi.org/10.25251/skin.7.supp.157","url":null,"abstract":"Introduction: The objective of this analysis was to evaluate facial IGA and the associated IGA success, stratified by the use of concomitant acne medications, among AV patients administered sarecycline in community practices across the U.S. \u0000Methods: A single-arm, prospective cohort study (PROSES) was conducted with moderate-to-severe non-nodular AV patients >9 years who were prescribed sarecycline in real-world community practices in the US. Facial IGA of AV status was collected on a five-point adjectival response scale (0(clear)-4(severe)). IGA success at week-12 was defined as >2-grade improvement and score 0-clear or 1-almost clear at week-12. Proportion of patients achieving IGA success was analyzed, stratified by the use of any concomitant AV medication during the study (Yes vs. No (monotherapy)). \u0000Results: A total of 253 AV patients completed the study (adults 60.08% (mean age 26.63); pediatric 39.92% (mean age 14.81); female: 66.40%; white/caucasian: 68.38%, african-american: 8.70%; other races: 22.92%). Per IGA at baseline, 86.56% & 13.44% had moderate and severe AV, respectively. Key concomitant treatments for AV observed during the study included: topical retinoids (24.51%), topical antibiotics (13.44%), benzoyl peroxide (5.93%), topical dapsone (5.14%) and other (17.00%; predominantly adapalene/benzoyl peroxide). Half of the patients (49.80%) were on sarecycline monotherapy (i.e., did not use any concomitant treatments for AV). For the overall study cohort, IGA success at week-12 was 58.89%. At week-12, IGA success was 59.84% among patients using concomitant AV medications, and 57.94% among patients using no concomitant AV medications (i.e., on sarecycline monotherapy). \u0000Conclusion: Within the study cohort administered sarecycline, a narrow-spectrum, tetracycline-derived antibiotic, for 12 weeks, majority of patients achieved IGA success at week-12, and the outcomes were similar among patients on sarecycline monotherapy and those on concomitant AV medications.","PeriodicalId":74803,"journal":{"name":"Skin (Milwood, N.Y.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47645906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-03-13DOI: 10.25251/skin.7.supp.131
L. Kircik, Z. Draelos, L. Stein Gold, A. Jacobson
{"title":"Use of Combination Halobetasol Propionate/Tazarotene Lotion in Difficult-to-Treat Psoriasis and TNF-α Mechanism of Action","authors":"L. Kircik, Z. Draelos, L. Stein Gold, A. Jacobson","doi":"10.25251/skin.7.supp.131","DOIUrl":"https://doi.org/10.25251/skin.7.supp.131","url":null,"abstract":"","PeriodicalId":74803,"journal":{"name":"Skin (Milwood, N.Y.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42172580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-03-13DOI: 10.25251/skin.7.supp.183
M. Nestor, Haowei Han, Faraz Yousefian, Ciaran Smythe
{"title":"The efficacy and safety of aminolevulinic acid 20% topical solution activated by pulsed dye laser and blue light for the treatment of facial cutaneous squamous cell carcinoma in situ","authors":"M. Nestor, Haowei Han, Faraz Yousefian, Ciaran Smythe","doi":"10.25251/skin.7.supp.183","DOIUrl":"https://doi.org/10.25251/skin.7.supp.183","url":null,"abstract":"","PeriodicalId":74803,"journal":{"name":"Skin (Milwood, N.Y.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42240104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-03-13DOI: 10.25251/skin.7.supp.168
J. Guenther, Christine N. Bailey, K. Ahmed, Clare E. Johnson, B. Martin, Sarah Kur, Maki Yamamoto
{"title":"Clinical use of the 31-gene expression profile for informing sentinel lymph node biopsies: a prospective, multicenter study","authors":"J. Guenther, Christine N. Bailey, K. Ahmed, Clare E. Johnson, B. Martin, Sarah Kur, Maki Yamamoto","doi":"10.25251/skin.7.supp.168","DOIUrl":"https://doi.org/10.25251/skin.7.supp.168","url":null,"abstract":"","PeriodicalId":74803,"journal":{"name":"Skin (Milwood, N.Y.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41925610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-03-13DOI: 10.25251/skin.7.supp.117
J. Bagel, A. Armstrong, R. Warren, K. Papp, D. Thaçi, A. Menter, J. Cather, M. Augustin, L. Hippeli, C. Daamen, C. Griffiths
Introduction: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved by the US FDA for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Deucravacitinib was significantly more efficacious than placebo or apremilast and was well tolerated in previous reports from the phase 3 POETYK PSO-1 trial. Here, we examined response rates through Week 52 from this trial in subgroups defined by previous biologic, systemic (biologic/nonbiologic), and/or oral systemic treatment. Methods: PSO-1, a multicenter, double-blind trial, enrolled adults with moderate to severe plaque psoriasis. Patients with previous phototherapy, systemic treatment, and/or biologic treatment completed washout periods (4 weeks–6 months) before study entry, depending on treatment. Patients were randomized 2:1:1 to deucravacitinib 6 mg QD, placebo, or apremilast 30 mg BID; this analysis focused on deucravacitinib and placebo patients. Placebo patients switched to deucravacitinib at Week 16. PASI 75 and sPGA 0/1 were evaluated through Week 52 by prior treatment (biologic, systemic [biologic/nonbiologic], oral systemic) and by biologic- and systemic-naive patients. Nonresponder imputation was used for all reported endpoints. Results: 332 patients were randomized to deucravacitinib and 166 to placebo. At baseline, 34.3% of deucravacitinib patients and 44.0% of placebo patients received prior oral systemic treatment, 60.2% and 65.7% received prior systemic (biologic/nonbiologic) treatment, and 39.2% and 38.0% received prior biologic treatment, respectively. Week 52 PASI 75 response rates were similar in patients receiving deucravacitinib from baseline (65.1%) and placebo patients switching to deucravacitinib at Week 16 (68.3%). Findings with deucravacitinib were similar to those in placebo patients switching to deucravacitinib regardless of prior systemic (65.5%/68.1%), oral (70.2%/69.2%), or biologic (61.5%/61.8%) treatment, and in patients with no prior systemic (64.4%/68.6%) or biologic (67.3%/72.2%) treatment. Similarly, sPGA 0/1 response rates were comparable in deucravacitinib versus placebo patients in the overall population (52.7%/53.8%) and in the prior systemic (53.0%/55.3%), prior oral systemic (57.0%/53.8%), prior biologic (47.7%/45.5%), systemic-naive (52.3%/51.0%), and biologic-naive (55.9%/58.9%) cohorts. Conclusion: Deucravacitinib was effective through 52 weeks for moderate to severe plaque psoriasis regardless of previous systemic treatment. Placebo patients switching to deucravacitinib at Week 16 achieved PASI 75 and sPGA 0/1 similar to patients continuously treated with deucravacitinib.
{"title":"Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy by prior treatment in the phase 3 POETYK PSO-1 trial","authors":"J. Bagel, A. Armstrong, R. Warren, K. Papp, D. Thaçi, A. Menter, J. Cather, M. Augustin, L. Hippeli, C. Daamen, C. Griffiths","doi":"10.25251/skin.7.supp.117","DOIUrl":"https://doi.org/10.25251/skin.7.supp.117","url":null,"abstract":"Introduction: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved by the US FDA for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Deucravacitinib was significantly more efficacious than placebo or apremilast and was well tolerated in previous reports from the phase 3 POETYK PSO-1 trial. Here, we examined response rates through Week 52 from this trial in subgroups defined by previous biologic, systemic (biologic/nonbiologic), and/or oral systemic treatment. \u0000Methods: PSO-1, a multicenter, double-blind trial, enrolled adults with moderate to severe plaque psoriasis. Patients with previous phototherapy, systemic treatment, and/or biologic treatment completed washout periods (4 weeks–6 months) before study entry, depending on treatment. Patients were randomized 2:1:1 to deucravacitinib 6 mg QD, placebo, or apremilast 30 mg BID; this analysis focused on deucravacitinib and placebo patients. Placebo patients switched to deucravacitinib at Week 16. PASI 75 and sPGA 0/1 were evaluated through Week 52 by prior treatment (biologic, systemic [biologic/nonbiologic], oral systemic) and by biologic- and systemic-naive patients. Nonresponder imputation was used for all reported endpoints. \u0000Results: 332 patients were randomized to deucravacitinib and 166 to placebo. At baseline, 34.3% of deucravacitinib patients and 44.0% of placebo patients received prior oral systemic treatment, 60.2% and 65.7% received prior systemic (biologic/nonbiologic) treatment, and 39.2% and 38.0% received prior biologic treatment, respectively. Week 52 PASI 75 response rates were similar in patients receiving deucravacitinib from baseline (65.1%) and placebo patients switching to deucravacitinib at Week 16 (68.3%). Findings with deucravacitinib were similar to those in placebo patients switching to deucravacitinib regardless of prior systemic (65.5%/68.1%), oral (70.2%/69.2%), or biologic (61.5%/61.8%) treatment, and in patients with no prior systemic (64.4%/68.6%) or biologic (67.3%/72.2%) treatment. Similarly, sPGA 0/1 response rates were comparable in deucravacitinib versus placebo patients in the overall population (52.7%/53.8%) and in the prior systemic (53.0%/55.3%), prior oral systemic (57.0%/53.8%), prior biologic (47.7%/45.5%), systemic-naive (52.3%/51.0%), and biologic-naive (55.9%/58.9%) cohorts. \u0000Conclusion: Deucravacitinib was effective through 52 weeks for moderate to severe plaque psoriasis regardless of previous systemic treatment. Placebo patients switching to deucravacitinib at Week 16 achieved PASI 75 and sPGA 0/1 similar to patients continuously treated with deucravacitinib.","PeriodicalId":74803,"journal":{"name":"Skin (Milwood, N.Y.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49380060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mycosis Fungoides (MF) is the most common form of cutaneous T-cell lymphoma, a rare condition which typically presents with erythematous patches and plaques, skin nodules and/or tumors. Advanced disease may progress to a more aggressive form known as a large-cell transformation (LCT). MF may be easily confused for psoriasis, a deep fungal infection, and pyoderma gangrenosum. Psoriasis and MF share common features associated with the abnormal functioning of T cells, and in the absence of an infectious process, pyoderma gangrenosum (PG) may be considered. Definitive diagnosis relies upon histopathology revealing characteristic features of MF including cerebriform nuclei, intraepidermal Pautrier microabscesses, epidermotropism and haloed lymphocytes, ruling out the other etiologies. Here is a case of a 62-year-old male with an atypical case of MF with LCT who presented with worsening skin eruption and a large draining ulcerated abdominal plaque. MF is typically a slow and indolent disease with multiple treatment options. Brentuximab vedotin (BV) is a monoclonal antibody targeting the CD30 antigen on cancer cells and is increasingly used in the treatment of MF patients with LCT. The patient was referred to hematology/oncology where further workup revealed CD30 positive large T-cells. He was started on BV and has already shown signs of significant disease regression.
{"title":"A Man with Worsening Scaling Plaques and a New Onset Large Draining Ulcerated Tumor","authors":"A. Taylor, Hannah Pile, D. Altman","doi":"10.25251/skin.7.2.6","DOIUrl":"https://doi.org/10.25251/skin.7.2.6","url":null,"abstract":"Mycosis Fungoides (MF) is the most common form of cutaneous T-cell lymphoma, a rare condition which typically presents with erythematous patches and plaques, skin nodules and/or tumors. Advanced disease may progress to a more aggressive form known as a large-cell transformation (LCT). MF may be easily confused for psoriasis, a deep fungal infection, and pyoderma gangrenosum. Psoriasis and MF share common features associated with the abnormal functioning of T cells, and in the absence of an infectious process, pyoderma gangrenosum (PG) may be considered. Definitive diagnosis relies upon histopathology revealing characteristic features of MF including cerebriform nuclei, intraepidermal Pautrier microabscesses, epidermotropism and haloed lymphocytes, ruling out the other etiologies. Here is a case of a 62-year-old male with an atypical case of MF with LCT who presented with worsening skin eruption and a large draining ulcerated abdominal plaque. MF is typically a slow and indolent disease with multiple treatment options. Brentuximab vedotin (BV) is a monoclonal antibody targeting the CD30 antigen on cancer cells and is increasingly used in the treatment of MF patients with LCT. The patient was referred to hematology/oncology where further workup revealed CD30 positive large T-cells. He was started on BV and has already shown signs of significant disease regression.","PeriodicalId":74803,"journal":{"name":"Skin (Milwood, N.Y.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47576033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-03-13DOI: 10.25251/skin.7.supp.170
Greg Stevens, B. Jansen, T. Arnold, J. Rock, J. Wood, L. Clarke, M. Hyde
Background: Pigmented lesion evaluation remains a challenging aspect of dermatology. The DermTech Melanoma Test (DMT) is a non-invasive gene-expression test designed to rule-out melanoma. It consists of the pigmented lesion assay, which detects RNA products of Long Intergenic Non-Coding RNA 00518 (LINC00518) and Preferentially Expressed Antigen in Melanoma (PRAME), and an add-on assay for DNA promoter mutations in telomerase reverse transcriptase (TERT). This registry study examines the concordance of PRAME detection by polymerase chain reaction (PCR) in samples obtained non-invasively prior to biopsy and PRAME detection by immunohistochemistry (IHC) on the same lesions after biopsy. Methods: Between April 2021 and March 2022, multiple geographically diverse sites throughout the US submitted data to a registry to assess real-world use of the DMT. Approximately 8,000 clinically atypical lesions were tested. After receiving the test result, providers followed their clinical judgement for biopsy decision. When lesions expressed genomic markers (LINC, PRAME, and/or TERT) and were biopsied, pathology reports were also submitted to the registry. The presence or absence of PRAME by immunohistochemistry (IHC) was reviewed and compared to the detection of PRAME by PCR from the DMT on the same lesion. Results: At the 1-year mark of the registry, there were roughly 8,000 unique entries. Of those, 1,021 (12.8%) were positive for one or more of the DMT genomic markers. One thousand three lesions (98.2%) had records available. Pathologists used PRAME IHC for 102 lesions (10.2%). Of those, 40 (39.2%) were positive by IHC, and 62 (60.8%) were negative by IHC. PRAME positivity by PCR correlated with PRAME positivity by IHC in 35 of 40 lesions (87.5%). Conversely, PRAME was detected using PCR in 28 of 62 lesions (45.2%) where it was not detected using IHC. Conclusions: The higher sensitivity of PCR compared to IHC may explain the higher concordance when PRAME is positive by IHC than when it is negative by IHC. In this data set, when PRAME is positive by IHC it is usually also positive by PCR. When PRAME is negative by IHC, it can still be detected by PCR in a substantial percentage of cases. The increased sensitivity of PCR is likely due to several factors, including its detection of the PRAME mRNA and sampling of the entire lesion. As such, PRAME PCR status may aid pathologists in understanding the risk of melanoma even when IHC is negative. Further research is warranted to understand the clinical implications of PRAME PCR versus IHC positivity.
{"title":"Concordance of Preferentially Expressed Antigen in Melanoma by Non-Invasively Collected Polymerase Chain Reaction and Immunohistochemistry on Paraffin Embedded Tissue","authors":"Greg Stevens, B. Jansen, T. Arnold, J. Rock, J. Wood, L. Clarke, M. Hyde","doi":"10.25251/skin.7.supp.170","DOIUrl":"https://doi.org/10.25251/skin.7.supp.170","url":null,"abstract":"Background: \u0000Pigmented lesion evaluation remains a challenging aspect of dermatology. The DermTech Melanoma Test (DMT) is a non-invasive gene-expression test designed to rule-out melanoma. It consists of the pigmented lesion assay, which detects RNA products of Long Intergenic Non-Coding RNA 00518 (LINC00518) and Preferentially Expressed Antigen in Melanoma (PRAME), and an add-on assay for DNA promoter mutations in telomerase reverse transcriptase (TERT). This registry study examines the concordance of PRAME detection by polymerase chain reaction (PCR) in samples obtained non-invasively prior to biopsy and PRAME detection by immunohistochemistry (IHC) on the same lesions after biopsy. \u0000Methods: \u0000Between April 2021 and March 2022, multiple geographically diverse sites throughout the US submitted data to a registry to assess real-world use of the DMT. Approximately 8,000 clinically atypical lesions were tested. After receiving the test result, providers followed their clinical judgement for biopsy decision. When lesions expressed genomic markers (LINC, PRAME, and/or TERT) and were biopsied, pathology reports were also submitted to the registry. The presence or absence of PRAME by immunohistochemistry (IHC) was reviewed and compared to the detection of PRAME by PCR from the DMT on the same lesion. \u0000Results: \u0000At the 1-year mark of the registry, there were roughly 8,000 unique entries. Of those, 1,021 (12.8%) were positive for one or more of the DMT genomic markers. One thousand three lesions (98.2%) had records available. Pathologists used PRAME IHC for 102 lesions (10.2%). Of those, 40 (39.2%) were positive by IHC, and 62 (60.8%) were negative by IHC. PRAME positivity by PCR correlated with PRAME positivity by IHC in 35 of 40 lesions (87.5%). Conversely, PRAME was detected using PCR in 28 of 62 lesions (45.2%) where it was not detected using IHC. \u0000Conclusions: \u0000The higher sensitivity of PCR compared to IHC may explain the higher concordance when PRAME is positive by IHC than when it is negative by IHC. In this data set, when PRAME is positive by IHC it is usually also positive by PCR. When PRAME is negative by IHC, it can still be detected by PCR in a substantial percentage of cases. The increased sensitivity of PCR is likely due to several factors, including its detection of the PRAME mRNA and sampling of the entire lesion. As such, PRAME PCR status may aid pathologists in understanding the risk of melanoma even when IHC is negative. Further research is warranted to understand the clinical implications of PRAME PCR versus IHC positivity. ","PeriodicalId":74803,"journal":{"name":"Skin (Milwood, N.Y.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48556192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Blue rubber bleb nevus syndrome (BRBNS), sometimes called Bean syndrome, is a rare sporadic congenital vascular disorder characterized by multiple venous malformations in various organ systems, most commonly the skin and gastrointestinal tract. The presence of characteristic skin lesions is often the first suggestion of this diagnosis, though chronic anemia and intestinal bleeding are also commonly present. We report a case of a patient with painful lesions on the plantar surfaces of the feet and a new cutaneous growth on the left labia majora. The plantar lesions were treated with Nd:YAG laser and the lesion on the labia majora was removed with a shave biopsy.
{"title":"Treatment of Cutaneous Lesions in a Case of Blue Rubber Bleb Nevus Syndrome","authors":"S. Seck, Taylor A. Bullock, S. Khetarpal","doi":"10.25251/skin.7.2.16","DOIUrl":"https://doi.org/10.25251/skin.7.2.16","url":null,"abstract":"Blue rubber bleb nevus syndrome (BRBNS), sometimes called Bean syndrome, is a rare sporadic congenital vascular disorder characterized by multiple venous malformations in various organ systems, most commonly the skin and gastrointestinal tract. The presence of characteristic skin lesions is often the first suggestion of this diagnosis, though chronic anemia and intestinal bleeding are also commonly present. We report a case of a patient with painful lesions on the plantar surfaces of the feet and a new cutaneous growth on the left labia majora. The plantar lesions were treated with Nd:YAG laser and the lesion on the labia majora was removed with a shave biopsy.","PeriodicalId":74803,"journal":{"name":"Skin (Milwood, N.Y.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43213342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Literature has demonstrated that medical students have discrepancies in their knowledge and their execution of best practices concerning sun protection. Additionally, despite knowing the harms of tanning, medical students acknowledge that they desire tan skin. A survey was sent to medical students at a Southeastern institution to determine their knowledge of sun safety and their personal practices. The survey was distributed through institutional emails and student messaging applications. Current medical students at the home institution were eligible to complete the survey. The survey was designed with guidelines from the American Academy of Dermatology in mind. Chi-square analysis was performed by SPSS Version 28.0.1.1 (14). The majority of medical students are knowledgeable of best sun protective practices, though many students do not carry out these practices. For example, 88% of students know to reapply sunscreen every 2 hours; however, only 28% always reapply at the correct interval. Several demographic differences were present between self-reported race and gender groups in the knowledge, behaviors, and tanning questions. Medical students are knowledgeable of best practices for preventing sun damage; however, their personal behaviors can deviate and societal pressure for some students to have “tanned” skin is challenging to overcome.
文献表明，医学生在防晒知识和最佳实践的执行方面存在差异。此外，尽管知道晒黑的危害，医科学生承认他们渴望晒黑的皮肤。一份调查发给了东南部一所机构的医科学生，以确定他们对阳光安全的了解和个人做法。该调查是通过机构电子邮件和学生短信应用程序分发的。在本院就读的医科学生有资格完成调查。这项调查是根据美国皮肤病学会的指导方针设计的。采用SPSS Version 28.0.1.1(14)进行卡方分析。大多数医学生都知道最好的防晒措施，尽管许多学生没有执行这些措施。例如，88%的学生知道每两小时补涂一次防晒霜;然而，只有28%的人总是在正确的时间间隔重新应用。在知识、行为和晒黑问题上，自我报告的种族和性别群体之间存在一些人口统计学差异。医科学生了解防止阳光伤害的最佳做法;然而，他们的个人行为可能会偏离常规，对一些学生来说，“晒黑”皮肤的社会压力很难克服。
{"title":"Sunscreen Knowledge and Sun Protective Behaviors among Medical Students at a Southern US Institution","authors":"M. Olivet, Lauren C. S. Kole","doi":"10.25251/skin.7.2.3","DOIUrl":"https://doi.org/10.25251/skin.7.2.3","url":null,"abstract":"Literature has demonstrated that medical students have discrepancies in their knowledge and their execution of best practices concerning sun protection. Additionally, despite knowing the harms of tanning, medical students acknowledge that they desire tan skin. A survey was sent to medical students at a Southeastern institution to determine their knowledge of sun safety and their personal practices. The survey was distributed through institutional emails and student messaging applications. Current medical students at the home institution were eligible to complete the survey. The survey was designed with guidelines from the American Academy of Dermatology in mind. Chi-square analysis was performed by SPSS Version 28.0.1.1 (14). The majority of medical students are knowledgeable of best sun protective practices, though many students do not carry out these practices. For example, 88% of students know to reapply sunscreen every 2 hours; however, only 28% always reapply at the correct interval. Several demographic differences were present between self-reported race and gender groups in the knowledge, behaviors, and tanning questions. Medical students are knowledgeable of best practices for preventing sun damage; however, their personal behaviors can deviate and societal pressure for some students to have “tanned” skin is challenging to overcome.","PeriodicalId":74803,"journal":{"name":"Skin (Milwood, N.Y.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42506151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：